Dose Recommendations for Prostrate-specific Membrane Antigen Positron Emission Tomography (PSMA PET) Guided Boost...

Prostrate-specific membrane antigen positron emission tomography (PSMA-PET) imaging has led to an increase in identifiable small volume metastatic disease in prostate adenocarcinoma. There is clinical equipoise in how to treat these using radiotherapy regimens. The aim of this study is to determine an adequate dosing regimen for small volume lymphatic metastases in prostate adenocarcinoma.

The authors first estimated the cell count of small volume metastases in prostate adenocarcinoma and then used a Poisson distribution-based estimation of the tumour control probability distribution, the required doses for 95% and 99% probabilities of tumour sterilisation were calculated using the linear quadratic formula.

Lymph node metastases of 3, 5, and 10 mm diameter were estimated to harbour 1.4, 6.5, and 52.3 million clonogens, respectively. When attempting for a 95% tumour control probability, estimated BEDs of 116.5, 127.0, and 141.1Gy were required. This translated to doses of 26.0, 27.3, and 29.0Gy in 5 fraction regimens. When attempting for a 99% tumour control probability, estimated biological effective doses (BEDs) of 127.6, 138.1, and 152.2 Gy were required. This translated to doses of 27.4, 28.6, and 30.2 Gy in 5 fraction regimens.

In prostate cancers with small-volume metastatic disease, doses can be adjusted according to tumour size without likely to compromise tumour control. This would have positive implications on radiotherapy planning and possibly lead to decreased risks of toxicity in scenarios where planning difficulty is encountered. Clinical evaluation of efficacy and safety for these dose regimens is warranted.